Interest in epicardial adipose tissue (EAT) is growing rapidly, and research in this area
appeals to a broad, multidisciplinary audience. EAT is unique in its anatomy and …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …

The obesity epidemic is closely associated with the rising prevalence and severity of
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple …

Background Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with
increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic …

There are no licensed treatments for non-alcoholic fatty liver disease (NAFLD), but three
different classes of antihyperglycaemic drugs—peroxisome proliferator-activated receptor …

To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for
treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

Epicardial adipose tissue has unique properties that distinguish it from other depots of
visceral fat. Rather than having distinct boundaries, the epicardium shares an unobstructed …

Fat accumulation outside subcutaneous adipose tissue often has unfavourable effects on
systemic metabolism. In addition to non-alcoholic fatty liver disease, which has received …